Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/92255
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Al-Ejeh, F. | - |
dc.contributor.author | Pajic, M. | - |
dc.contributor.author | Shi, W. | - |
dc.contributor.author | Kalimutho, M. | - |
dc.contributor.author | Miranda, M. | - |
dc.contributor.author | Nagrial, A. | - |
dc.contributor.author | Chou, A. | - |
dc.contributor.author | Biankin, A. | - |
dc.contributor.author | Grimmond, S. | - |
dc.contributor.author | Brown, M. | - |
dc.contributor.author | Khanna, K. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Clinical Cancer Research, 2014; 20(12):3187-3197 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.uri | http://hdl.handle.net/2440/92255 | - |
dc.description.abstract | PURPOSE: To develop effective combination therapy against pancreatic ductal adenocarcinoma (PDAC) with a combination of chemotherapy, CHK1 inhibition, and EGFR-targeted radioimmunotherapy. EXPERIMENTAL DESIGN: Maximum tolerated doses were determined for the combination of gemcitabine, the CHK1 inhibitor PF-477736, and Lutetium-177 ((177)Lu)-labeled anti-EGFR antibody. This triple combination therapy was investigated using PDAC models from well-established cell lines, recently established patient-derived cell lines, and fresh patient-derived xenografts. Tumors were investigated for the accumulation of (177)Lu-anti-EGFR antibody, survival of tumor-initiating cells, induction of DNA damage, cell death, and tumor tissue degeneration. RESULTS: The combination of gemcitabine and CHK1 inhibitor PF-477736 with (177)Lu-anti-EGFR antibody was tolerated in mice. This triplet was effective in established tumors and prevented the recurrence of PDAC in four cell line-derived and one patient-derived xenograft model. This exquisite response was associated with the loss of tumor-initiating cells as measured by flow cytometric analysis and secondary implantation of tumors from treated mice into treatment-naïve mice. Extensive DNA damage, apoptosis, and tumor degeneration were detected in the patient-derived xenograft. Mechanistically, we observed CDC25A stabilization as a result of CHK1 inhibition with consequent inhibition of gemcitabine-induced S-phase arrest as well as a decrease in canonical (ERK1/2 phosphorylation) and noncanonical EGFR signaling (RAD51 degradation) as a result of EGFR inhibition. CONCLUSIONS: Our study developed an effective combination therapy against PDAC that has potential in the treatment of PDAC. | - |
dc.description.statementofresponsibility | Fares Al-Ejeh, Marina Pajic, Wei Shi, Murugan Kalimutho, Mariska Miranda, Adnan M. Nagrial, Angela Chou, Andrew V. Biankin, Sean M. Grimmond, Michael P. Brown, and Kum Kum Khanna | - |
dc.language.iso | en | - |
dc.publisher | American Association for Cancer Research | - |
dc.rights | © 2014 American Association for Cancer Research | - |
dc.source.uri | http://dx.doi.org/10.1158/1078-0432.ccr-14-0048 | - |
dc.subject | Australian Pancreatic Cancer Genome Initiative | - |
dc.subject | Tumor Cells, Cultured | - |
dc.subject | Animals | - |
dc.subject | Mice, Inbred BALB C | - |
dc.subject | Mice, Inbred NOD | - |
dc.subject | Humans | - |
dc.subject | Mice | - |
dc.subject | Mice, SCID | - |
dc.subject | Carcinoma, Pancreatic Ductal | - |
dc.subject | Pancreatic Neoplasms | - |
dc.subject | DNA Damage | - |
dc.subject | Pyrazoles | - |
dc.subject | Benzodiazepinones | - |
dc.subject | Protein Kinases | - |
dc.subject | Deoxycytidine | - |
dc.subject | Antimetabolites, Antineoplastic | - |
dc.subject | Antibodies, Monoclonal | - |
dc.subject | Blotting, Western | - |
dc.subject | Immunoenzyme Techniques | - |
dc.subject | Radioimmunotherapy | - |
dc.subject | Combined Modality Therapy | - |
dc.subject | Xenograft Model Antitumor Assays | - |
dc.subject | Signal Transduction | - |
dc.subject | Apoptosis | - |
dc.subject | Cell Proliferation | - |
dc.subject | Phosphorylation | - |
dc.subject | Drug Synergism | - |
dc.subject | Female | - |
dc.subject | ErbB Receptors | - |
dc.subject | Checkpoint Kinase 1 | - |
dc.subject | Gemcitabine | - |
dc.title | Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-14-0048 | - |
dc.relation.grant | http://purl.org/au-research/grants/arc/FT130101417 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Brown, M. [0000-0002-5796-1932] [0000-0002-6678-1407] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.